Minakem-flap
Minakem-flap

Find Clinical Drug Pipeline Developments & Deals by Galmed Pharmaceuticals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aramchol

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co

            Deal Size: $10.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 16, 2021

            Details:

            Galmed Pharmaceuticals' lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aramchol

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 19, 2021

            Details:

            The symposium will primarily focus on Aramchol, currently in Phase 3 for non-alcoholic steatohepatitis (NASH) and liver fibrosis, and Amilo-5MER for chronic inflammatory disorders.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ASC41,Aramchol

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ASC41

            Highest Development Status: Undisclosed Product Type: Small molecule

            Recipient: Ascletis Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 10, 2020

            Details:

            ASC41 is an oral thyroid hormone receptor beta agonist and Aramchol is a novel synthetic small molecule, a conjugate of cholic acid and arachidic acid, linked by a stable amide group. The team will work together combining both the therapies for the treatment of NASH.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Amilo-5MER

            Therapeutic Area: Immunology Product Name: Amilo-5MER

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Hebrew University of Jerusalem

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 06, 2020

            Details:

            The 5 amino acids sequence of Amilo-5MER is homologue to a specific MTADV sequence in the human CD44 variant found in synovial fluid cells from joints of rheumatoid arthritis (RA) patients.